Patents by Inventor Varsha Sitaraman

Varsha Sitaraman has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20230313187
    Abstract: The present invention provides methods and compositions for stable genetic modification of cultured mammalian cells. The genetic modifications can be used to produce cultured mammalian cells for therapeutic or diagnostic purposes.
    Type: Application
    Filed: September 3, 2021
    Publication date: October 5, 2023
    Applicant: DNA TWOPOINTO INC.
    Inventors: Jeremy MINSHULL, Maggie LEE, Varsha SITARAMAN, Oren BESKE, Ferenc BOLDOG
  • Publication number: 20230295625
    Abstract: The present invention provides methods and compositions for stable genetic modification of cultured mammalian cells. The genetic modifications can be used to produce- cultured mammalian cells for therapeutic of diagnostic purposes.
    Type: Application
    Filed: December 29, 2022
    Publication date: September 21, 2023
    Inventors: Jeremy MINSHULL, Ferenc BOLDOG, Varsha SITARAMAN, Maggie LEE
  • Publication number: 20220112500
    Abstract: The present invention provides methods and compositions for stable genetic modification of cultured mammalian cells. The genetic modifications can be used to produce cultured mammalian cells for therapeutic or diagnostic purposes.
    Type: Application
    Filed: November 4, 2021
    Publication date: April 14, 2022
    Applicant: DNA TWOPOINTO INC.
    Inventors: JEREMY MINSHULL, FERENC BOLDOG, VARSHA SITARAMAN, MAGGIE LEE
  • Patent number: 11162102
    Abstract: The present invention provides methods and compositions for stable genetic modification of cultured mammalian cells. The genetic modifications can be used to produce cultured mammalian cells for therapeutic or diagnostic purposes.
    Type: Grant
    Filed: May 11, 2020
    Date of Patent: November 2, 2021
    Assignee: DNA TWOPOINTO INC.
    Inventors: Jeremy Minshull, Maggie Lee, Varsha Sitaraman, Ferenc Boldog
  • Publication number: 20210332331
    Abstract: The invention provides adeno-associated virus (AAV) replication (Rep) sequences. In one embodiment, the invention provides nucleotide sequences encoding a chimeric protein, wherein the encoded chimeric protein contains a wild type AAV Rep inhibitory amino acid sequence, and wherein the nucleotide sequences contain a scrambled and/or deoptimized polynucleotide sequence encoding the wild type AAV Rep inhibitory amino acid sequence. The invention provides vectors, cells, and viruses containing the invention's sequences. Also provided are methods for detecting portions of the AAV Rep inhibitory amino acid sequence, which reduce replication and/or infection and/or productive infection by viruses. The invention's compositions and methods are useful for site-specific integration and/or expression of heterologous sequences by recombinant adeno-associated virus (rAAV) vectors and by rAAV virus particles, such as hybrid viruses (e.g., Ad-AAV) comprising such vectors.
    Type: Application
    Filed: February 4, 2021
    Publication date: October 28, 2021
    Inventors: Wadie F. Bahou, Patrick Hearing, Varsha Sitaraman
  • Patent number: 10947514
    Abstract: The invention provides adeno-associated virus (AAV) replication (Rep) sequences. In one embodiment, the invention provides nucleotide sequences encoding a chimeric protein, wherein the encoded chimeric protein contains a wild type AAV Rep inhibitory amino acid sequence, and wherein the nucleotide sequences contain a scrambled and/or deoptimized polynucleotide sequence encoding the wild type AAV Rep inhibitory amino acid sequence. The invention provides vectors, cells, and viruses containing the invention's sequences. Also provided are methods for detecting portions of the AAV Rep inhibitory amino acid sequence, which reduce replication and/or infection and/or productive infection by viruses. The invention's compositions and methods are useful for site-specific integration and/or expression of heterologous sequences by recombinant adeno-associated virus (rAAV) vectors and by rAAV virus particles, such as hybrid viruses (e.g., Ad-AAV) comprising such vectors.
    Type: Grant
    Filed: January 23, 2019
    Date of Patent: March 16, 2021
    Assignee: The Research Foundation For The State University Of New York
    Inventors: Wadie F. Bahou, Patrick Hearing, Varsha Sitaraman
  • Publication number: 20200362344
    Abstract: The present invention provides methods and compositions for stable genetic modification of cultured mammalian cells. The genetic modifications can be used to produce cultured mammalian cells for therapeutic or diagnostic purposes.
    Type: Application
    Filed: May 11, 2020
    Publication date: November 19, 2020
    Inventors: Jeremy Minshull, Maggie Lee, Varsha Sitaraman, Ferenc Boldog
  • Publication number: 20190292525
    Abstract: The invention provides adeno-associated virus (AAV) replication (Rep) sequences. In one embodiment, the invention provides nucleotide sequences encoding a chimeric protein, wherein the encoded chimeric protein contains a wild type AAV Rep inhibitory amino acid sequence, and wherein the nucleotide sequences contain a scrambled and/or deoptimized polynucleotide sequence encoding the wild type AAV Rep inhibitory amino acid sequence. The invention provides vectors, cells, and viruses containing the invention's sequences. Also provided are methods for detecting portions of the AAV Rep inhibitory amino acid sequence, which reduce replication and/or infection and/or productive infection by viruses. The invention's compositions and methods are useful for site-specific integration and/or expression of heterologous sequences by recombinant adeno-associated virus (rAAV) vectors and by rAAV virus particles, such as hybrid viruses (e.g., Ad-AAV) comprising such vectors.
    Type: Application
    Filed: January 23, 2019
    Publication date: September 26, 2019
    Inventors: Wadie F. Bahou, Patrick Hearing, Varsha Sitaraman
  • Patent number: 10214730
    Abstract: The invention provides adeno-associated virus (AAV) replication (Rep) sequences. In one embodiment, the invention provides nucleotide sequences encoding a chimeric protein, wherein the encoded chimeric protein contains a wild type AAV Rep inhibitory amino acid sequence, and wherein the nucleotide sequences contain a scrambled and/or deoptimized polynucleotide sequence encoding the wild type AAV Rep inhibitory amino acid sequence. The invention provides vectors, cells, and viruses containing the invention's sequences. Also provided are methods for detecting portions of the AAV Rep inhibitory amino acid sequence, which reduce replication and/or infection and/or productive infection by viruses. The invention's compositions and methods are useful for site-specific integration and/or expression of heterologous sequences by recombinant adeno-associated virus (rAAV) vectors and by rAAV virus particles, such as hybrid viruses (e.g., Ad-AAV) comprising such vectors.
    Type: Grant
    Filed: July 9, 2015
    Date of Patent: February 26, 2019
    Assignee: The Research Foundation For The State University Of New York
    Inventors: Wadie F. Bahou, Patrick Hearing, Varsha Sitaraman
  • Publication number: 20160002607
    Abstract: The invention provides adeno-associated virus (AAV) replication (Rep) sequences. In one embodiment, the invention provides nucleotide sequences encoding a chimeric protein, wherein the encoded chimeric protein contains a wild type AAV Rep inhibitory amino acid sequence, and wherein the nucleotide sequences contain a scrambled and/or deoptimized polynucleotide sequence encoding the wild type AAV Rep inhibitory amino acid sequence. The invention provides vectors, cells, and viruses containing the invention's sequences. Also provided are methods for detecting portions of the AAV Rep inhibitory amino acid sequence, which reduce replication and/or infection and/or productive infection by viruses. The invention's compositions and methods are useful for site-specific integration and/or expression of heterologous sequences by recombinant adeno-associated virus (rAAV) vectors and by rAAV virus particles, such as hybrid viruses (e.g., Ad-AAV) comprising such vectors.
    Type: Application
    Filed: July 9, 2015
    Publication date: January 7, 2016
    Inventors: Wadie F. Bahou, Patrick Hearing, Varsha Sitaraman
  • Publication number: 20140155469
    Abstract: The invention provides adeno-associated virus (AAV) replication (Rep) sequences. In one embodiment, the invention provides nucleotide sequences encoding a chimeric protein, wherein the encoded chimeric protein contains a wild type AAV Rep inhibitory amino acid sequence, and wherein the nucleotide sequences contain a scrambled and/or deoptimized polynucleotide sequence encoding the wild type AAV Rep inhibitory amino acid sequence. The invention provides vectors, cells, and viruses containing the invention's sequences. Also provided are methods for detecting portions of the AAV Rep inhibitory amino acid sequence, which reduce replication and/or infection and/or productive infection by viruses. The invention's compositions and methods are useful for site-specific integration and/or expression of heterologous sequences by recombinant adeno-associated virus (rAAV) vectors and by rAAV virus particles, such as hybrid viruses (e.g., Ad-AAV) comprising such vectors.
    Type: Application
    Filed: April 19, 2012
    Publication date: June 5, 2014
    Applicant: THE RESEARCH FOUNDATION OF STATE UNIVERSITY OF NEW YORK
    Inventors: Wadie F. Bahou, Patrick Hearing, Varsha Sitaraman